Proto, Claudia

Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review

Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology

Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging

Cited by 340

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 244

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 209

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme

Grossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 111

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 54

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

Prelaj, A., Galli, E. G., Miskovic, V., Pesenti, M., Viscardi, G., Pedica, B., Mazzeo, L., Bottiglieri, A., Provenzano, L., Spagnoletti, A., et al. (2023) · Frontiers in Oncology

Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging

Cited by 39

Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review

Galli, G., Corrao, G., Imbimbo, M., Proto, C., Signorelli, D., Ganzinelli, M., Zilembo, N., Vitali, M., de Braud, F., Garassino, M. C., et al. (2018) · Lung Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 29